Clinical Trial Update: Supracondylar Distal Femur Fractures and Abaloparatide [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating abaloparatide for supracondylar distal femur fractures has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fracture of Femur

Drugs mentioned

• Abaloparatide (abaloparatide)

Snippet

Sponsor: Daniel Horwitz | Conditions: Femoral Fractures | Phase 4 | Status: WITHDRAWN